Ambient Voice Technology (AVT) is rapidly transforming the healthcare landscape. These AI-powered tools, designed to transcribe and summarise clinician-patient interactions, have been celebrated for their potential to reduce administrative burden and free up clinician time for more meaningful patient care. But with innovation comes regulation—and NHS England has made it clear that the use of these tools must now meet stringent compliance standards.
From Hype to Healthcare Regulation
Until recently, many AVT tools were marketed as non-medical devices. This positioning allowed them to enter clinical environments without UKCA or CE marking. But that changed on 27 April 2025, when NHS England released new guidance outlining the safe and appropriate adoption of AVT and AI scribing technologies.
Developed in consultation with the Medicines and Healthcare products Regulatory Agency (MHRA), the guidance made a critical distinction: AVT tools that go beyond transcription to include summarisation are to be considered Software as a Medical Device (SaMD). This has far-reaching implications, particularly for compliance with UK medical device regulations.
A Warning Ignored
Despite clear guidance, NHS England has observed the continued deployment of AVT solutions that fail to meet the required standards. These tools have entered clinical settings via direct commissioning by healthcare organisations or through unofficial free trials led by clinicians—often without proper governance, approval, or assurance.
In response, the National Chief Clinical Information Officer issued a Priority Notification on 9 June 2025, mandating the immediate cessation of any AVT product that:
- Lacks MHRA Class I medical device registration (if summarisation is performed),
- Has not completed clinical safety (DCB0160) and data protection (DPIA) assessments,
- Fails to meet platform assurance standards such as DTAC, DSPT, or Cyber Essentials Plus,
- Has not been approved through relevant ICB or Trust governance channels.
The notice leaves no room for ambiguity: organisations and clinicians using non-compliant tools are now personally liable for any resulting risk or harm.
Consequences for Vendors—and the NHS
For AVT vendors, especially those who had not positioned themselves as medical device manufacturers, the regulatory pivot has triggered a frantic response. Many are now rushing to register their products as Class I medical devices, often under the category of Digital Dictation Systems (as listed in the MHRA’s Public Access Registration Database – PARD).
However, this is not a rubber stamp. While Class I devices are self-certified, manufacturers must maintain a comprehensive technical file to demonstrate compliance—and the MHRA can request this documentation at any time. Simply registering without generating a compliant file carries serious regulatory risk, including possible enforcement action.
For vendors unfamiliar with medical device regulations, building compliant documentation will likely require specialist support—either through consultants or internal investment in regulatory expertise. Meanwhile, failure to comply not only bars their product from NHS use but also risks long-term exclusion from NHS procurement frameworks.
What Comes Next?
NHS England’s intervention marks a significant tightening of digital health governance. As AI and voice technologies continue to reshape clinical workflows, it’s clear that the NHS expects vendors—and clinicians—to treat these tools as serious medical technologies, not just productivity enhancers.
The message is clear: innovation is welcome, but compliance is non-negotiable.
